New COVID-19 Study | Exercise | Nutrition, Cancer Information Highlights, May 28, 2020

National Cancer Institute sent this bulletin at 05/28/2020 09:42 AM EDT
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share
Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
NCI COVID-19 in Cancer Patients Study
icons representing medical images, such as person with mask, chart, x-ray, test tube   Learn about the NCI COVID-19 in Cancer Patients Study (NCCAPS), a natural history study of COVID-19 in people with cancer. The knowledge gained from this study will help doctors better manage treatment for people with cancer and COVID-19.
For Women with Breast Cancer, Regular Exercise May Improve Survival
two middle aged women walking outside, laughing   A new study adds to the body of research linking exercise and longer survival in some women with breast cancer. Read about how being physically active is one way that survivors can improve their health.
Nutrition Label Updated
nutrition label   The Nutrition Facts label that is displayed on food packages has been updated for the first time in 20 years. Learn how the label has changed to reflect the latest science, including links between nutrition and disease.
Video—Cancer and Other Illnesses during COVID-19: How young patients and families can cope

If you missed the live broadcast, you can now watch the recording of our Facebook Live event. Listen to our panel of experts discuss ways young people with cancer or other serious illnesses and their families can cope with the added stress of the COVID-19 pandemic.
FDA Approvals
New Treatment for Metastatic Lung Cancer

We’ve updated our drug summaries for nivolumab (Opdivo) and ipilimumab (Yervoy). The Food and Drug Administration (FDA) approved this drug combination as first-line therapy for certain adults with metastatic non-small cell lung cancer that has the PD-L1 protein.
New Treatments for Prostate Cancer

We’ve updated our drug summaries for olaparib (Lynparza) and rucaparib (Rubraca). FDA recently approved these drugs for treatment of adults with prostate cancer that has spread, has certain germline or somatic mutations, and has not responded to treatments that lower testosterone levels.
 
Also of Interest

Expanded Information on Coronavirus and Cancer

Many people with cancer have questions about coronavirus. This new web page presents information about COVID-19, including:

  • what patients with cancer should know about the virus
  • how the virus may affect their cancer care
  • research studies for people with cancer and COVID-19
  • news about NCI’s response to COVID-19
Types of Clinical Trials

There are many types of clinical trials. Each type is designed to answer different research questions and will help researchers learn things that will help people in the future. Learn more about natural history studies and other types of trials.
Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.